Catabasis Pharmaceuticals, Inc. (CATB): Price and Financial Metrics
CATB Price/Volume Stats
Current price | $8.54 | 52-week high | $47.82 |
Prev. close | $9.18 | 52-week low | $6.31 |
Day low | $8.46 | Volume | 98,800 |
Day high | $9.21 | Avg. volume | 491,246 |
50-day MA | $9.82 | Dividend yield | N/A |
200-day MA | $13.56 | Market Cap | 33.34M |
CATB Stock Price Chart Interactive Chart >
Catabasis Pharmaceuticals, Inc. (CATB) Company Bio
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The company was incorporated in 2008 and is based in Cambridge, Massachusetts.
Latest CATB News From Around the Web
Below are the latest news stories about Catabasis Pharmaceuticals Inc that investors may wish to consider to help them evaluate CATB as an investment opportunity.
Astria Therapeutics to Present at Upcoming Investor ConferencesBOSTON, September 10, 2021--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the following upcoming virtual investor conferences: |
Catabasis Renames As Astria Therapeutics With New Disease FocusOnce-struggling, Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is looking to hit the reset button with a new name and focus. Catabasis has been dragging for several years, weighed down mainly by the failure of the edasalonexent program in Duchenne muscular dystrophy. After it failed in a late-stage study, Catabasis decided to discontinue the development of the drug altogether. Then, in February, Catabasis acquired another local company, a rare disease startup called Quellis Biosciences. Now, Cata |
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company FocusBOSTON, September 08, 2021--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc. ("Astria" or the "Company"). The name Astria originates from the Greek word for star, reflecting the Company’s commitment to having patients serve as guiding stars. Astria’s mission is to bring hope with life-changing therapies to patients and families. Astria expects t |
Do Institutions Own Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Shares?The big shareholder groups in Catabasis Pharmaceuticals, Inc. ( NASDAQ:CATB ) have power over the company. Large... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning! |
CATB Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | N/A |
3-year | -37.57% |
5-year | -81.94% |
YTD | N/A |
2023 | N/A |
2022 | N/A |
2021 | 0.00% |
2020 | -63.79% |
2019 | 35.24% |
Loading social stream, please wait...